CAR T-Cell Therapy in Non-Hodgkin’s Lymphoma (NHL)

CAR T-Cell Therapy in Non-Hodgkin’s Lymphoma (NHL)

CAR T-cell therapy has become a groundbreaking treatment option for Non-Hodgkin’s Lymphoma, particularly in cases that are relapsed or resistant to standard therapies. This cutting-edge therapy involves genetically engineering a patient’s T cells to express chimeric antigen receptors (CARs) that specifically target and destroy cancer cells. It has demonstrated strong efficacy, especially in aggressive forms like Diffuse Large B-Cell Lymphoma (DLBCL), and has received regulatory approvals, including from the FDA. However, the therapy still faces challenges, such as potentially serious side effects (e.g., cytokine release syndrome and neurological toxicity), as well as its high cost. Continued advancements in CAR T-cell research and ongoing clinical trials are expected to broaden its application across NHL subtypes and improve treatment effectiveness and safety.

Want more data like this? Get the infographic now

https://www.delveinsight.com/infographics/car-t-cell-therapy-for-non-ahodgkins-lymphoma-market?utm_source=infographics&utm_medium=promotion&utm_campaign=akpr 

Epidemiological Segmentation

CAR T-cell therapy eligibility for NHL is segmented by:

• Incident cases by indication (e.g., Mantle Cell Lymphoma, DLBCL, Follicular Lymphoma, Marginal Zone Lymphoma, PMBCL, CLL/SLL)
  
  

• Indication-specific eligible patient populations for CAR T-cell therapy
  
  

Epidemiology Highlights (2023)

• An estimated 126,000 patients in the 7MM were eligible for CAR T-cell therapy in 2023.
  
  

• DLBCL was the most common NHL subtype in the EU4 and the UK, accounting for around 32,000 cases.
  
  

• Japan reported approximately 23,700 incident cases of NHL across key CAR T-suitable subtypes in 2023.
  
  

Visualize the trends—then explore the data behind them in our latest report : Click Here

Market Overview

• The US market for CAR T-cell therapy in NHL was valued at approximately USD 1.2 billion in 2023.
  
  

Market Drivers

• Strong clinical success in hard-to-treat NHL cases.
  
  

• Rapid technological progress in CAR T-cell development.
  
  

• A growing number of FDA-approved CAR T therapies.
  
  

• Rising demand for individualized and immune-based treatments.
  
  

Market Barriers

• High production and administration costs of CAR T-cell therapies.
  
  

• Limited availability of treatment centers with necessary infrastructure.
  
  

• Risks of serious adverse events, including CRS and neurotoxicity.
  
  

• Regulatory hurdles and insurance coverage issues impacting accessibility.
  
  

Download the full infographic to uncover detailed insights : Click Here

Pipeline Therapies

Emerging CAR T-cell products include:

• Cemacabtagene ansegedleucel
  
  

• Rapcabtagene autoleucel
  
  

• Zamtocabtagene autoleucel
  
  

• AUTO4
  
  

• CD30.CAR-T
  
  

• PMB-CT01
  
  

• And others
  
  

Key Industry Players

• Allogene Therapeutics
  
  

• Novartis
  
  

• Miltenyi Biomedicine
  
  

• Mustang Bio
  
  

• Crispr Therapeutics
  
  

• 2seventy Bio
  
  

• Imugene
  
  

• Among others
  
  

Make informed decisions—start with the full report

https://www.delveinsight.com/report-store/car-t-cell-therapy-for-non-hodgkins-lymphoma-market?utm_source=infographics&utm_medium=promotion&utm_campaign=akpr